Related Experiment Videos
Effect of paroxetine on the electrocardiogram
J G Edwards1, A Goldie, S Papayanni-Papasthatis
1Department of Psychiatry, Royal South Hants Hospital, Southampton, UK.
Psychopharmacology
|January 1, 1989
Summary
Paroxetine, an antidepressant, showed no significant cardiac side effects in a study of patients with major depression. Electrocardiogram (ECG) results indicated minimal impact on heart function during a 4-week treatment period.
Area of Science:
- Pharmacology
- Cardiology
- Psychiatry
Background:
- Selective serotonin reuptake inhibitors (SSRIs) like paroxetine are widely prescribed for major depression.
- Understanding the cardiac safety profile of antidepressants is crucial for patient management.
Purpose of the Study:
- To evaluate the electrocardiographic (ECG) effects of paroxetine in patients with major depression.
- To determine if therapeutic doses of paroxetine induce clinically relevant cardiac changes.
Main Methods:
- 20 patients with major depression underwent high-speed ECG recordings before and after 4 weeks of paroxetine or placebo treatment.
- Measurements included heart rate, PR interval, QTc interval, T-wave height, QRS width, and blood pressure.
- All measurements were conducted blinded to treatment allocation and interval.
Main Results:
- No significant changes in heart rate, PR, QTc intervals, or T-wave height were observed in either the paroxetine or placebo groups.
- A small, statistically significant increase in QRS width was noted in the paroxetine group compared to a slight decrease in the placebo group.
- No significant changes in blood pressure were detected.
Conclusions:
- Paroxetine, at therapeutic doses, does not appear to cause clinically significant cardiac adverse effects in young, healthy individuals with major depression.
- The observed minor change in QRS width is unlikely to be clinically relevant.
- Further research may be warranted for specific patient populations with pre-existing cardiovascular conditions.